الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 153 |  |  |
| | | from | 153 | | |
Abstract
Introduction: PTC is the most prevalent type of thyroid cancer and its unique nuclear features are the primary diagnostic indicator. However, some of these features can also be present in other thyroid lesions, which may lead to diagnostic challenge.
Aim of work: Evaluate the diagnostic value of NPC2 and CD56 in distinguishing PTC from other thyroid lesions with mimicking features.
Materials and Methods: Seventy tissue blocks representing benign (20 FA and 10 NH) and malignant thyroid lesions (30 PTC and 10 FC) were randomly selected for the current study. Institutional Review Board” IRB”, Minya University has reviewed & approved submitted research proposal” Approval No. 404/04/2021.
Results: Among the studied different thyroid lesions, NPC2 high expression was detected in 51.4% of cases. A statistically significant association was detected between NPC2 expression and patient sex (p-value=0.044), histologic subtype (p-value <0.001) and PTC versus non-PTC lesions (p-value <0.001). In PTC cases, NPC2 high expression was detected in 83.3% of cases. A statistically significant association was detected between NPC2 expression and pathological tumor stage (p-value=0.013). CD56 negative expression was found in 48.6% of cases of studied thyroid lesions. A statistically significant relation was found between CD56 expression and histologic subtype, benign versus malignant lesions and PTC versus non-PTC lesions (p-value <0.001, <0.001 and <0.001 respectively). In PTC, CD56 negative expression was detected in 86.7% of cases. A statistically significant relation was found between CD56 expression and site of lesion and lymph node metastasis (p-value=0.029 and 0.009 respectively).
Conclusion: NPC2 and CD56 can be a helpful immunohistochemical markers in distinguishing PTC from other thyroid mimics.